Status:
TERMINATED
AZD2066 Neuropathic Pain - Mechanical Hypersensitivity
Lead Sponsor:
AstraZeneca
Collaborating Sponsors:
Quintiles, Inc.
Conditions:
Neuropathic Pain
Mechanical Hypersensitivity
Eligibility:
All Genders
18-80 years
Phase:
PHASE2
Brief Summary
The purpose of this study is to investigate if 28 days of treatment with AZD2066 compared to placebo can relieve the pain arising from the nervous system when the patients are touched by something tha...
Eligibility Criteria
Inclusion
- Provision of informed consent prior to any study specific procedures.
- Male or non-fertile females
- Painful symptoms due to neuropathic pain for a period of 3 months to 5 years, associated with mechanical allodynia and/or punctate hyperalgesia.
Exclusion
- Other pain that may confound assessment of neuropathic pain.
- Diagnosis of any severe neurological disease.
- History of significant psychiatric disease/condition and/or history of psychotic disorders among first degree relatives.
Key Trial Info
Start Date :
August 1 2009
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
November 1 2010
Estimated Enrollment :
87 Patients enrolled
Trial Details
Trial ID
NCT00939094
Start Date
August 1 2009
End Date
November 1 2010
Last Update
September 27 2012
Active Locations (38)
Enter a location and click search to find clinical trials sorted by distance.
1
Research Site
Tucson, Arizona, United States
2
Research Site
Los Angeles, California, United States
3
Research Site
Sacramento, California, United States
4
Research Site
San Francisco, California, United States